Early use of recombinant human erythropoietin promotes neurobehavioral development in preterm infants / 中国当代儿科杂志
Chinese Journal of Contemporary Pediatrics
;
(12): 586-588, 2008.
Artigo
em Chinês
| WPRIM
| ID: wpr-317386
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the effect of the early use of recombinant human erythropoietin (rhu-EPO) on neurobehavioral development in preterm infants.</p><p><b>METHODS</b>Forty-four preterm infants (30 males and 14 females) were randomly divided into two groups Rhu-EPO treatment and untreated control (n=22 each). From postnatal day 7, the Rhu-EPO treatment group received intravenous rhu-EPO (250 IU/kg3 times weekly) for 4 weeks. A Neonatal Behavioral Neurological Assessment (NBNA) was performed at 40 weeks of corrected gestational age. A Gesell Development Schedule was used to evaluate neurological development 6 and 12 months after birth.</p><p><b>RESULTS</b>The NBNA score in the rhu-EPO treatment group (36.20+/-0.75) was significantly higher than that in the control group (34.40+/-1.05) at 40 weeks of corrected gestational age (P<0.05). The developmental quotient of fine motor in the rhu-EPO treatment group was significantly higher than that in the control group 6 months after birth (P<0.05). By 12 months after birth, the developmental quotient of gross motor, fine motor and language in the rhu-EPO treatment group was significantly higher than that in the control group (P<0.05).</p><p><b>CONCLUSIONS</b>Early use of Rhu-EPO can promote neurobehavioral development in preterm infants.</p>
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Fisiologia
/
Encéfalo
/
Proteínas Recombinantes
/
Recém-Nascido Prematuro
/
Desenvolvimento Infantil
/
Eritropoetina
/
Comportamento do Lactente
/
Usos Terapêuticos
/
Doenças do Prematuro
/
Anemia
Limite:
Feminino
/
Humanos
/
Masculino
/
Recém-Nascido
Idioma:
Chinês
Revista:
Chinese Journal of Contemporary Pediatrics
Ano de publicação:
2008
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS